BCAS1 anticorps (AA 542-584) (FITC)

N° du produit ABIN1391420

Détail du produit anti-BCAS1 anticorps (FITC)

Antigène: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Épitope: AA 542-584

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BCAS1 est conjugé à/à la FITC

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human BCAS1

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur BCAS1

Antigène: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Autre désignation: BCAS1/NABC1 (BCAS1 Produits)

Synonymes: anticorps AIBC1, anticorps NABC1, anticorps 2210416M21Rik, anticorps 9030223A09Rik, anticorps AI841227, anticorps Band83, anticorps Pmes-2, anticorps BCAS1, anticorps MGC152145, anticorps breast carcinoma amplified sequence 1, anticorps BCAS1, anticorps Bcas1

Sujet:

Synonyms: AIBC 1, AIBC1, Amplied and overexpressed in breast cancer, BCAS 1, BCAS1, BCAS1_HUMAN, Breast carcinoma amplied sequence 1, Breast carcinoma-amplied sequence 1, Novel amplied in breast cancer 1.

Background: NaBC1 is a protein found amplified in most breast carcinoma forms. It is expressed primarily as a cytoplasmic, detergent-stable homodimer that has a tendency to interact with DYNLL1 (PIN) and DYNLL2. Breast tumor lines that exhibit 20q13.2 gene amplification express much higher levels of the protein as compared to the levels found in other breast cancer lines that do not overexpress the NaBC1 mRNA. However, this upregulation does not affect growth rate or anchoring abilities of a cell, indicating the oncogenic properties of NaBC1 differ from that of other oncogenes.